Replies to post #80415 on Biotech Values

[drbio45]

>So, Multaq is likely to compete and in time replace Amiodarone because of the safety advantages, imo. <

It would be approved for afib, Amiodarone isn't.

[mcbio]

Re: Multaq (vs. ARYX compound)

1. In the DIONOSYS (head-to-head vs Amiodarone) trial - Multaq showed to be less effective at suppressing AF but safer. ...
So, Multaq is likely to compete and in time replace Amiodarone because of the safety advantages, imo.

And, at least in theory, ARYX's AF compound, ATI-2042, should have a shot to effectively compete against Multaq since it was designed to retain Amiodarone's efficacy, but be much safer. More trials are needed but so far so good.

[DewDiligence]

At $2,600 per year, SNY’s Multaq will be one of the most expensive pills for a chronic common disease:

http://www.reuters.com/article/marketsNews/idINLS59493520090728